ReviewPharmacology research & perspectives2025
Mangiferin Against Respiratory Diseases: Pharmacological Targets and Prospects.
Review in Pharmacology research & perspectives, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mangiferin Against Respiratory Diseases: Pharmacological Targets and Prospects.Pharmacology research & perspectives · 2025Review
- Pulmonary hypertension: etiology and anti-inflammatory treatment pathways of natural products.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory diseases are associated with high mortality worldwide. Respiratory infections can lead to the emergence of chronic respiratory diseases. Scientists are constantly striving to identify new therapies with reduced side effects. The rise of antibiotic resistance and the scarcity of effective treatments further necessitate the development of novel therapeutics specific to respiratory diseases. Extensive research has been conducted on natural products that could be effective against respiratory diseases. Mangiferin, a polyphenol with a C-glycosyl xanthone structure, is a bioactive phytochemical that has potential applications in the treatment of respiratory tract infections. Mangiferin could be a therapeutic option against respiratory diseases because of its ability to target a variety of pharmacological pathways implicated in the development of these infections. It has been shown to limit infections, lower inflammation, control immune responses, and enhance host defense mechanisms. This review provides comprehensive insight into mangiferin's potential against various respiratory disorders, focusing on its pharmacological activity and therapeutic prospects. Despite the potential of mangiferin against respiratory problems-related pathobiology, additional scientific validation through clinical trials is required before the clinical application of mangiferin in the management of respiratory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.